Kennedy Capital Management, Inc. Cullinan Oncology, Inc. Transaction History

Kennedy Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.17 - $19.02 $770,662 - $1.44 Million	-75,778 Reduced 47.36%	84,234 $1.44 Million
Q4 2023 Feb 14, 2024	SELL	$7.89 - $10.23 $2.6 Million - $3.37 Million	-329,434 Reduced 67.31%	160,012 $1.63 Million
Q3 2023 Nov 14, 2023	SELL	$9.05 - $11.72 $474,907 - $615,018	-52,476 Reduced 9.68%	489,446 $4.43 Million
Q2 2023 Aug 14, 2023	SELL	$8.8 - $13.4 $378,576 - $576,468	-43,020 Reduced 7.35%	541,922 $5.83 Million
Q1 2023 May 15, 2023	SELL	$10.2 - $11.91 $292,199 - $341,185	-28,647 Reduced 4.67%	584,942 $5.98 Million
Q4 2022 Feb 14, 2023	SELL	$9.72 - $13.62 $246,120 - $344,872	-25,321 Reduced 3.96%	613,589 $6.47 Million
Q3 2022 Nov 14, 2022	BUY	$11.82 - $15.42 $7.15 Million - $9.32 Million	604,563 Added 1760.16%	638,910 $8.19 Million
Q2 2022 Aug 10, 2022	BUY	$7.31 - $13.55 $251,076 - $465,401	34,347 New	34,347 $440,000

146

67.6M

612K

118K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $499M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.